OINDPnews


Aptar Pharma banner

Business

Pharmascience to discontinue pms-sodium cromoglycate inhalation solution

Canadian pharma company Pharmascience has announced that it will stop manufacturing pms-sodium cromoglycate inhalation solution due to a 95% drop in demand over the past 15 years. Pharmascience now says it will sell pms-sodium cromoglycate for $24.23 per 50-nebule unit until it runs out of inventory. According to a November 19, 2021 Canadian news report, the … [Read more...] about Pharmascience to discontinue pms-sodium cromoglycate inhalation solution

Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham

Birmingham Biotech said that it has licensed a carrageenan/gellan antiviral nasal spray from the University of Birmingham and intends to market the spray in the UK and in Asian countries for protection against COVID-19 starting in early 2022. The license excludes marketing rights in India but includes the rest of the world. Birmingham Biotech currently sells … [Read more...] about Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham

Pulmatrix and Cipla resolve dispute over Pulmazole funding

According to Pulmatrix, a dispute between Pulmatrix and Cipla over funding related to the development of Pulmazole intraconazole DPI (PUR 1900) has been resolved. In May 2021, Pulmatrix announced that Cipla had failed to provide 50% of the development costs for Pulmazole and had therefore breached the terms of their development and commercialization agreement for the … [Read more...] about Pulmatrix and Cipla resolve dispute over Pulmazole funding

Perrigo launches Marinomed’s Carragelose nasal spray in France and Scandinavia

Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray is being marketed for the prevention of respiratory viruses under the name Physiomer in the Scandinavian countries and as Phytosun … [Read more...] about Perrigo launches Marinomed’s Carragelose nasal spray in France and Scandinavia

CF Foundation, Innoviva make equity investments in Armata Pharmaceuticals

Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company's common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata, has invested a further $4 million. The funds will be used to support further development of the company's lead … [Read more...] about CF Foundation, Innoviva make equity investments in Armata Pharmaceuticals

ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said. According to the announcement, funds will also be used for expanding the company's pipeline and for adding manufacturing capabilities. Earlier … [Read more...] about ReCode Therapeutics raises $80 million for development of inhaled therapies for CF, PCD

Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray

Shandong Luoxin Pharmaceutical will pay $2 million up front plus milestone payments of up to $20 million to acquire exclusive rights to develop, manufacture, and commercialize Marninomed's Budesolv budesonide nasal spray in China, the company has announced. In April 2019, Marinomed announced that a Phase 3 trial of Budesolv for the treatment of allergic rhinitis had … [Read more...] about Shandong Luoxin gets Chinese rights to Marinomed’s Budesolv budesonide nasal spray